-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
Two products from Guangxiang Pharmaceutical and Guolong Pharmaceutical, both subsidiaries of Shijiazhuang Sihua Pharmaceutical Group, have been recognized as Provincial Manufacturing Single-Champion Products.
Category:
TIME：2022-12-31
Recently, the Hebei Provincial Department of Industry and Information Technology announced the fourth batch of provincial manufacturing Single-Champion Enterprises and Single-Champion Products. Among them, Metronidazole produced by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, and Hydroxyethyl Starch produced by Hebei Guolong Pharmaceutical Co., Ltd. were both recognized as Hebei Province’s Manufacturing Single-Champion Products.
In recent years, Shijiazhuang Sihua Pharmaceutical Group has fully leveraged its advantages across the entire industrial chain, aligning innovation initiatives with the needs of the value chain and actively advancing its “finished dosage forms plus active pharmaceutical ingredients” development strategy. Its subsidiaries, Guangxiang Pharmaceutical and Guolong Pharmaceutical, have continued to grow and strengthen, integrating and adopting world-leading process technologies and equipment, deepening collaboration with research institutions, and accelerating the development of specialty, high-value-added APIs. These efforts have effectively promoted optimization and transformation of the product mix, thereby empowering the company’s high-quality development.
As a large-scale API industrialization base specializing in the production, R&D, and export of bulk APIs and high-value-added specialty APIs, Guangxiang Pharmaceutical has, in recent years, focused its research on the independent R&D of key specialty and high-end APIs as well as on breakthrough innovations in critical API synthesis technologies. The company has continuously accelerated R&D efficiency and driven further innovation in API synthesis processes, with a strong emphasis on elevating quality standards. Through ongoing process optimization, critical quality control parameters for metronidazole—such as residual solvents, related impurities, and microbial limits—have been steadily improved, reaching internationally leading levels. As a result, the product has been recognized as a Hebei Province Quality Benchmark and has served as the lead entity in developing multiple national standards. Guangxiang Pharmaceutical’s metronidazole now holds the largest market share within Hebei Province and ranks among the top in the domestic market, enjoying widespread favor among downstream customers.
Guided by the principle of high-quality development, Guolong Pharmaceutical has integrated the Group’s superior resources to tackle key technological challenges, thereby resolving critical issues in its manufacturing processes, breaking through technical bottlenecks hindering industry growth, and continuously strengthening its competitive edge in the R&D and production of specialty APIs. The company’s refined, diversified, and high-end API products have garnered widespread attention and recognition from both the industry and society. Notably, its flagship hydroxyethyl starch product line is exclusively manufactured within the province and ranks among the top performers in domestic market sales.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
